版本:
中国

BRIEF-Crispr Therapeutics, Casebia Therapeutics announce exclusive development and option agreement with Stridebio

April 17 Crispr Therapeutics Ag

* Crispr Therapeutics and Casebia Therapeutics announce exclusive development and option agreement with Stridebio

* Crispr Therapeutics - under agreement, Stridebio will use proprietary platform to develop AAV vectors with improved properties

* Crispr Therapeutics - co, Casebia will have option to exclusively license aav vectors with desired properties for use in their in Vivo gene-editing programs

* Stridebio will receive development funding, milestones and royalties on licensed vectors

* Stridebio will retain certain rights to use Novel aav vectors for gene therapy applications Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐